Last reviewed · How we verify
Injection of Filgrastim
Injection of Filgrastim is a G-CSF agonist Small molecule drug developed by Centre Leon Berard. It is currently in Phase 2 development for Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reducing the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection.
Filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection. Used for Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reducing the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
At a glance
| Generic name | Injection of Filgrastim |
|---|---|
| Sponsor | Centre Leon Berard |
| Drug class | G-CSF agonist |
| Target | G-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that works by binding to its receptor on the surface of bone marrow cells, triggering the release of mature neutrophils into the bloodstream. This process helps to increase the number of neutrophils in the blood, which can help to prevent infections in patients undergoing chemotherapy or other treatments that suppress the immune system.
Approved indications
- Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
- Reducing the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy
Common side effects
- Bone pain
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models (PHASE2)
- A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia (PHASE2)
- A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injection of Filgrastim CI brief — competitive landscape report
- Injection of Filgrastim updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI
Frequently asked questions about Injection of Filgrastim
What is Injection of Filgrastim?
How does Injection of Filgrastim work?
What is Injection of Filgrastim used for?
Who makes Injection of Filgrastim?
What drug class is Injection of Filgrastim in?
What development phase is Injection of Filgrastim in?
What are the side effects of Injection of Filgrastim?
What does Injection of Filgrastim target?
Related
- Drug class: All G-CSF agonist drugs
- Target: All drugs targeting G-CSF receptor
- Manufacturer: Centre Leon Berard — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
- Indication: Drugs for Reducing the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy
- Compare: Injection of Filgrastim vs similar drugs
- Pricing: Injection of Filgrastim cost, discount & access